Basilea presents new research data on a biomarker for its novel oncology drug candidate BAL101553 at AACR
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea presents new research data on a biomarker for its novel oncology drug
candidate BAL101553 at AACR
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 4, 2012 - Research data on a potential biomarker
predicting response to Basilea's novel microtubule-targeting phase I oncology
drug candidate BAL101553 were presented at the American Association of Cancer
Research (AACR) Annual Meeting in Chicago, Illinois, USA.
BAL101553 is a novel small molecule that arrests tumor cell proliferation and
induces tumor cell death through a characteristic destabilizing effect on
microtubules, an intracellular network essential for cell division.
Anti-cancer activity of BAL101553 has been demonstrated across a broad panel of
preclinical models of human cancer, including those resistant against
conventional microtubule-targeting drugs such as taxanes or vinca alkaloids. The
injectable form of BAL101553 is currently being tested in a phase I clinical
program with patients suffering from advanced solid tumors. Phase I data are
expected in the second half of 2012.
Results of collaborative studies between the Basilea research group and the team
of Dr. Michael Boutros, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg,
Germany, were presented at AACR. These preclinical studies demonstrate that
BubR1 protein kinase function is required for the antiproliferative action of
BAL27862 (the active moiety of BAL101553) in tumor cells. BubR1 plays a key
regulatory role in the assembly of the microtubule mitotic spindle required for
cell division. Using small interfering RNA (siRNA) approaches and diverse cancer
models, it was found that susceptibility to BAL27862 correlated with BubR1
expression levels. The work presented at AACR provides a robust dataset across
tumor types, supportive of the further evaluation of BubR1 as a potential marker
of tumor response to BAL101553.
"The identification of BubR1 as a potential predictive biomarker, based on the
demonstrated correlation between BubR1 expression and sensitivity of cancer
cells to BAL101553, is a result of Basilea's strategy to ultimately optimize
treatment of cancer patients by selecting as early as possible those most likely
to benefit from this novel drug," said Dr. Laurenz Kellenberger, Basilea's Chief
Scientific Officer.
+------------------------------------------------------------------------------+
|Poster on BAL101553/BAL27862 at the AACR Annual Meeting 2012 |
| |
| * BubR1 function is required for the antiproliferative activity of the novel|
| microtubule-targeting drug BAL27862 (active moiety of the prodrug |
| BAL101553) - H. Lane, K. Burger, F. Bachmann, A. Tzankov, M. Boutros, D. |
| Gilbert; poster/abstract #3795 |
+------------------------------------------------------------------------------+
For further information please visit www.aacr.org
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Through the fully integrated research and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd. the company focuses on innovative pharmaceutical products in
the therapeutic areas of bacterial infections, fungal infections, oncology and
skin diseases, targeting the medical challenge of rising resistance and non-
response to current treatment options in the hospital and specialty care
setting. The Basilea group includes affiliates in European countries as well as
in China.
Basilea is currently marketing Toctino® (oral alitretinoin), approved in
European countries, Canada and Israel for the treatment of adults with severe
chronic hand eczema unresponsive to potent topical corticosteroids, in Denmark,
Finland, France, Germany, Norway, Switzerland and the United Kingdom and has
appointed distributors for Toctino® in other selected European markets, Canada,
Israel, Mexico and the Republic of Korea. In the U.S., oral alitretinoin is an
investigational drug. Topline data from the U.S. phase III study (HANDEL) on
oral alitretinoin have been recently reported. The results are consistent with
previous randomized international studies.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal infections, the
company has entered into a license, co-development and co-promotion agreement
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel anti-MRSA
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both Gram-
positive bacteria, including MRSA, and many clinically important Gram-negative
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel investigational antibiotic for the treatment of
resistant Gram-negative infections, and the oncology drug candidate BAL101553
for the treatment of drug-resistant cancers are in phase I clinical testing.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future, anticipated results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new information,
future events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, Ph.D. | Barbara Zink, Ph.D., MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.
Press release (PDF):
http://hugin.info/134390/R/1599990/504964.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1599990]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="First Majestic announces friendly Acquisition of Silvermex ResourcesDatum: 04.04.2012 - 07:15 Uhr
Sprache: Deutsch
News-ID 131882
Anzahl Zeichen: 8089
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea presents new research data on a biomarker for its novel oncology drug candidate BAL101553 at AACR"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
